NCT00278330View on ClinicalTrials.gov

Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2009

Conditions
Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRelapsing Chronic Myelogenous LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

alvocidib

Given by infusion

DRUG

vorinostat

Given orally

Trial Locations (1)

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00278330 - Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | Biotech Hunter | Biotech Hunter